Response to clozapine in a clinically identifiable subtype of schizophrenia: 22q11.2 deletions mediate side effect risk and dosage.


This research explored how individuals with 22q and schizophrenia respond to the medication clozapine, and how it differs from individuals with schizophrenia who do not have 22q. We found that a lower dose of clozapine and using preventative measures can help lower the risks of side effects for individuals with 22q.